Concord Wealth Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Concord Wealth Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2	Closed	-$717	–	833
2023 Q3	$717	Hold	2	–	–	﹤0.01%	961
2023 Q2	$758	Hold	2	–	–	﹤0.01%	967
2023 Q1	$958	Hold	2	–	–	﹤0.01%	900
2022 Q4	$841	Buy	+2	New	+$807	﹤0.01%	1101
2022 Q3	–	Sell	-2	Closed	-$1K	–	260
2022 Q2	$1K	Hold	2	–	–	﹤0.01%	1103
2022 Q1	$1K	Hold	2	–	–	﹤0.01%	1175
2021 Q4	$2K	Hold	2	–	–	﹤0.01%	1102
2021 Q3	$1K	Hold	2	–	–	﹤0.01%	809
2021 Q2	$1K	Hold	2	–	–	﹤0.01%	947
2021 Q1	$1K	Buy	+2	New	+$1.18K	﹤0.01%	885

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Concord Wealth Partners's BIO Position: Q4 2023 in Review

Concord Wealth Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 2 shares — an estimated $717 sold.

Concord Wealth Partners first reported a position in BIO in Q1 2021 and held it in 10 quarters. The position peaked at $2K in Q4 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

Concord Wealth Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
Concord Wealth Partners sold 2 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $717.
Concord Wealth Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 10 quarters.
Concord Wealth Partners's Bio-Rad Laboratories Class A position peaked at $2K in Q4 2021.
484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Concord Wealth Partners's 13F filing for Q4 2023, filed 6 Feb 2024.